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Objectives: The gut microbiome is a diverse and complex microbial ecosystem. In
patients with cystic ﬁbrosis (CF) this microbiome is inﬂuenced due to antibiotic
treatments, the enlarged mucus layer in the small intestine, the changed pH due
to the decreased bicarbonate transport in the intestinal lumen and the different
alimentary environment due to decreased release of digestive enzymes by the
pancreatic duct. These problems not only entail changes in the composition of
the gut microbiome, but also cause intestinal inﬂammation and affect the general
well-being of CF patients.
Methods: A shotgun metaproteomics approach is used to characterize and compare
the predominant members of the faecal microbiome. Faecal protein extracts obtained
from seven CF patients and their siblings were separated by SDS-PAGE and in-
gel digested. The tryptic peptides were analyzed using LC-ESI FT-ICR-MS. The
detected peptide sequences were analyzed using Unipept (http://unipept.ugent.be)
and Progenesis LC-MS was used to determine the differentially expressed proteins.
Conclusion: Unipept analysis shows that bacteria of the phylum Firmicutes, and in
particular several butyrate-producing bacteria were underrepresented in CF patients.
Butyrate serves as the preferred energy source for the colonocytes, has anti-
inﬂammatory effects and therefore aids in the improvement of the intestinal barrier.
Furthermore the differentially expressed protein study shows that four proteins of
the butyrate synthesis pathway (acetyl-CoA acetyltransferase, b-hydroxybutyryl-
CoA dehydrogenase, 3-hydroxybutyryl-CoA dehydratase and butyryl-CoA dehy-
drogenase) are less abundant in the faecal microbiome of CF patients.
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Objectives: Cultivation-independent analysis has revealed the polymicrobial nature
of CF lung infection. The literature increasingly suggests that low sputum microbial
diversity is associated with poor lung function in CF. The optimal means of proﬁling
bacterial diversity in routine CF care is unknown. We assessed the suitability of a
simple PCR-proﬁling tool, Ribosomal Intergenic Spacer Analysis (RISA), for the
investigation of sputum bacterial diversity.
Methods: Paired sputum samples were sent for routine microbiology and subjected
to total nucleic acids extraction using an automated method applied in standard
clinical virology. Microﬂuidics was used to separate RISA proﬁles ampliﬁed from
this DNA. 16S rRNA gene pyrosequencing was performed on a subset of samples
to evaluate the performance of RISA.
Results: RISA proﬁles were successfully ampliﬁed from 200 sputum samples
representative of 93 CF patients. 25% of these patients demonstrated RISA proﬁles
dominated by one of the following Gram negative bacteria: Burkholderia cepacia
complex, Ralstonia mannitolilytica, Stenotrophomonas maltophilia and Achro-
mobacter xylosoxidans. Pyrosequencing analysis conﬁrmed the loss of microbial
diversity in these samples. In 9 cases conventional microbiology failed to correctly
identify these dominant bacterial pathogens. The RISA proﬁles of UK CF patients
infected with the B. cenocepacia ET12 strain matched those of Czech patients
infected with the ST32 strain.
Conclusions: Infection with non-fermentative Gram negative bacterial species leads
to a loss in microbial diversity in CF that can be rapidly detected using a simple
RISA proﬁling method.
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Objectives: The objectives of the present project are to assess the composition
of airways microbiota in CF patients with a severe decline in lung function and
not responding to antimicrobial therapy, and to discover new opportunistic (non-
culturable) pathogens involved in pulmonary disease. Targeted antibiotic therapy
against other members of the polymicrobial community can contribute to resolve
pulmonary disease in CF patients.
Methods: Three groups of CF patients were investigated:
1. normal lung function/mild decline (FEV1, >70% of predicted),
2. moderate lung dysfunction (FEV1, 40 to 69% of predicted) and
3. severe lung dysfunction (FEV1 <40% predicted).
Within each group, “non-responder” CF patients who have showed a severe decline
in lung function (FEV1 5% in the last year) and did not respond to antimicrobial
therapy, and “stable CF patients” (having had no change in pulmonary function or
a rate decline in FEV1 equal to average value in the last year) has been enrolled.
Composition of CF microbiota was investigated by using advanced culture-based
methods and the molecular proﬁling method of Terminal Restriction Fragment
Length Polymorphism (T-RFLP).
Conclusion: Our preliminary ﬁndings suggest that combining culture-dependent
and culture-independent approaches provides a more comprehensive perspective of
CF microbiology than either approach alone. The results obtained will set the basis
to identify new targets for treatment and management of bacterial infections in
CF patients.
This work was supported by the Italian Cystic Fibrosis Foundation (grant
FFC#8/2012).
126 Changes in the microbiology of the pulmonary secretions in
cystic ﬁbrosis (CF) patients: Report on 4 different years during
25 years
L. Galanternik1, S. Lubovich2, S. Zaragoza2, V. Rodrı´guez2, M. Vazquez1,
A. Teper2. 1Hospital de Nin˜os Ricardo Gutie´rrez, Microbiology, Buenos Aires,
Argentina; 2Hospital de Nin˜os Ricardo Gutie´rrez, Respiratory Center, Buenos
Aires, Argentina
Our laboratory has been studying respiratory secretions of CF since 1987 and during
these 25 years lots of changes were observed.
The aim of this study was to analyse microbiological ﬁndings in 4 different years
between 1987 and 2011.
Sputum, oropharyngeal swab and BAL from 329 pts, aged 0.1−20 yo, collected in
1987, 1995, 2005 and 2011 were analysed. Samples were plated on 5% blood agar,
chocolate agar, CLED agar and mannitol salt agar. Since 2001 BCSA agar was
used, to enhance B. cepacia recovery.
The number of patients (cultures) in each year was 70 (108), 82 (217), 124 (384)
and 120 (498) in 1987, 1995, 2005 and 2011, respectively. The median (range) of
culture/patient was 1 (1−4), 2 (1−9), 3 (1−9) and 4 (1−11) in each year.
The percentages of patients’ isolates are presented in the table.
Percentages of patients’ isolates
1987 1995 2005 2011 p (1987 vs. 2011)
P. aeruginosa 76.6 72.8 58.6 44.4 <0.01
S. aureus 51.9 78.3 79.7 71.8 <0.01
MRSA 5.2 22.8 33.6 32.3 <0.01
H. inﬂuenzae 10.4 19.6 26.6 41.9 <0.01
B. cepacia 2.6 1.1 18.7 6.5 ns
A. xylosoxidans 0 0 4.7 4.8 ns
S. maltophilia 0 2.2 3.1 8.9 ns
Conclusions: A decrease in P. aeruginosa colonisation was observed. An increasing
rate of S aureus and MRSA colonisation was noted. A peak of B. cepacia
colonisation was detected in 2005.
